Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Inhaled vs. injected: which stops lung bleeding faster?

NCT ID NCT07212452

Symptom relief Sponsor: University of Health Sciences Lahore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether inhaling tranexamic acid works faster than receiving it through an IV to stop mild-to-moderate coughing up blood (hemoptysis). 172 patients aged 12 to 80 with infections or cancer-related bleeding took part. The goal was to see which method controls bleeding more quickly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

172 people

The number who actually took part.

Started

Aug 2025

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with mild to moderate hemoptysis \< 600ml/ 24 hours of age 12 to 80 years and both genders. 2. Patients with hemoptysis due to infective pathology. 3. Patients with hemoptysis due to malignant pathology. Exclusion Criteria: 1. Patients on antiplatelet therapy or aspirin 2. Hemoptysis after penetrating lung injury e.g. firearm injury 3. Patients with history of asthma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemoptysis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hemoptysis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemoptysis Nebulization Tranexamic acid

Contacts and locations

Locations

  • Services Hospital Lahore

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.